AB0816-PC Associations of autoimmune deseases with transient or permanent hip destruction

Background Associations of autoimmune diseases with transient or permanent hip destructions ABSTACT Autoimmune diseases associated with partial or total destruction of bone cartilage and the bone morrow of the hip in high risk patients can lead to a transient or permanent disability of the joint. Th...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Annals of the rheumatic diseases 2013-06, Vol.72 (Suppl 3), p.A1051-A1051
Hauptverfasser: Mandrakos, V., Kyvernitakis, M., Poulis, A., Kyvernitakis, I., Kyvernitakis, A., Poulis, S., Mandrakou, A.-F.
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Background Associations of autoimmune diseases with transient or permanent hip destructions ABSTACT Autoimmune diseases associated with partial or total destruction of bone cartilage and the bone morrow of the hip in high risk patients can lead to a transient or permanent disability of the joint. This condition may indicate a permanent handicap of the patient, an endoprothesis of the hip, insurance and health system costs as well as social restriction. Methods: METHODS Our working group including rheumatologists, orthopedic surgeons and gynecologists based on an 8 year experience conducted and investigated the impact of special therapy protocols, questionnaires on family case history and personal history for high risk factors (obesity, dyslipidemia, elevated uric acid and chronic pulmonary diseases) and habits as alcohol and smoking, medical charts of former diseases on patient outcome. Primary aim of this study was to investigate whether our protocol could prevent hip destruction based on diagnosis and therapy on time. Results: RESULTS We present: Tables Figures analyzing development of disease Figures presenting radiological findings before and after therapy DISCUSSION Analysis of the results Therapy protocols For cartilage For bone morrow For hip ischemia We investigate a total of 156 high risk patients. 16 patients (10.1%) presented additionally with an autoimmune disease (SLE, A.S., R.A., SJOGREN SYNDROME). Close patient surveillance was conducted over a period of 2 years. We conclude that apart from timely diagnosis, a therapy with the correct indication should include support of the cartilage, anti-resorptive therapy of the bone and prevention of hip ischemia. Disclosure of Interest None Declared
ISSN:0003-4967
1468-2060
DOI:10.1136/annrheumdis-2013-eular.3138